Want to see FLNA full AI Analyst Report?
FLNA Stock Chart & Stats
$0.89
$0.02(2.09%)
At close: 4:00 PM EDT
$0.89
$0.02(2.09%)
Day’s Range― - ―
52-Week Range$0.86 - $4.98
Previous CloseN/A
Volume114.73K
Average Volume (3M)356.28K
Market Cap
$48.79M
Enterprise Value-$25.19
Total Cash (Recent Filing)$82.68M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.04
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,307,896
10 Day Avg. Volume355,122
30 Day Avg. Volume356,284
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-3.02
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.00Price Target Upside461.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero debt provides structural financial flexibility for a development-stage biotech. Low leverage reduces bankruptcy risk and preserves optionality to fund R&D through equity raises, partnerships, or milestone financing without large fixed interest burdens.
Board & Governance SupportRe-election of directors, approval of an omnibus incentive amendment, and auditor ratification signal governance continuity and management alignment. Strong governance and retention tools support long-term execution, talent retention, and credibility with partners and investors.
Improved Cash Burn TrendA marked reduction in cash burn reflects sharper spending control or program prioritization, lengthening runway. Sustained lower outflows reduce near-term financing frequency and give management more time to advance programs or secure partnerships before dilutive raises.
Bears Say
No RevenueA complete absence of commercial revenue means the company lacks validated product sales or recurring cash inflows. Long-term value is therefore binary and dependent on successful clinical outcomes, licensing, or partnership deals to create sustainable revenues.
Persistent LossesLarge, recurring losses and volatility compress equity and increase dilution risk over time. Continued negative earnings make planning and investment in the pipeline dependent on external capital, raising execution risk if financing conditions tighten or milestones slip.
Eroding Equity & AssetsDeclining equity and assets materially reduce financial flexibility and bargaining power. With a smaller asset base, the company may face tougher terms in future financings or partnerships, increasing the likelihood of dilution or constrained investment in growth programs.
Filana Therapeutics News
FLNA FAQ
What was Filana Therapeutics’s price range in the past 12 months?
Filana Therapeutics lowest stock price was $0.86 and its highest was $4.98 in the past 12 months.
What is Filana Therapeutics’s market cap?
Filana Therapeutics’s market cap is $48.79M.
When is Filana Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Filana Therapeutics’s earnings last quarter?
Currently, no data Available
Is Filana Therapeutics overvalued?
According to Wall Street analysts Filana Therapeutics’s price is currently Undervalued.
Does Filana Therapeutics pay dividends?
Filana Therapeutics pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Filana Therapeutics dividends here
What is Filana Therapeutics’s EPS estimate?
Filana Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Filana Therapeutics have?
Filana Therapeutics has 48,307,896 shares outstanding.
What happened to Filana Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Filana Therapeutics?
Currently, no hedge funds are holding shares in FLNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Filana Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (461.80% Upside)
$5.00 (461.80% Upside)
Hedge Fund Trend
Increased
By 346.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.25%
Trailing 12-Months
Company Description
Filana Therapeutics
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
FLNA Stock 12 Month Forecast
Average Price Target
$5.00
▲(461.80% Upside)
Technical Analysis
Codexis
―
Seres Therapeutics
―
Anixa Biosciences
―
Cognition Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
1.99% Insiders
5.48% Mutual Funds
0.08% Other Institutional Investors
87.85% Public Companies and
Individual Investors